Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive Adenocarcinomas

NCT05101356 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT05101356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive Adenocarcinomas
Lead sponsor
University of California, Davis
Phase
Phase 1/2
Overall status
Suspended
Start date
January 13, 2021
Completion date
January 1, 2034
Enrollment
77 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adenocarcinoma, advanced malignant solid neoplasm, metastatic adenocarcinoma, metastatic malignant solid neoplasm, recurrent adenocarcinoma, recurrent malignant solid neoplasm